In CLL cells, the PPARα antagonists increased TNFα and decreased IL-10 release, as well as stimulated T cell proliferation in allogenic mixed lymphocytic reaction (22). This evidence concerns the gene PPARA and B-cell chronic lymphocytic leukemia.